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Under current legislation in Italy, Cannabis for medical purposes may be administered 
orally in the form of decoction or Cannabis oil extract. The scientific literature reports a 
number of preparation methods, mainly for oils, but no study is available that compares 
thoroughly, from a technological viewpoint, the Cannabis-based formulations currently 
administered to patients. With this in mind, this research work aimed to carry out specific 
formulation studies to design standard operating procedures for the preparation and 
optimization of Cannabis-based galenic formulations. Both decoctions and oils were 
prepared under different operating conditions to identify the most efficient process 
for the production of formulations with a high concentration of decarboxylated delta-
9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Regarding Cannabis oil, a new 
procedure has been developed that allows significantly higher recovery rates for THC and 
CBD compared with those for water-based extraction methods (decoction) and those for 
oil-based methods currently in use. Moreover, based on the results, it is possible to affirm 
that the prescription of Cannabis-based decoctions should not be the recommended 
first-choice solution for therapy, considering the low concentration of THC and CBD and, 
consequently, the high volume of decoction that the patient would have to ingest.
Keywords: medical Cannabis, Cannabis oil, delta-9-tetrahydrocannabinol, cannabidiol, galenic preparations, 
standard operating protocols
INTRODUCTION
In the past, Cannabis was widely used for its curative properties in traditional medicine. In the last 
century, it became the focus of attention for the abuse of its psychotropic effects. Consequently, the 
cultivation and sale of Cannabis were outlawed in many countries (Lafaye et al., 2017; Pisanti and 
Bifulco, 2019). However, in recent years, cannabinoids have seen a resurgence in consumption, in 
part, because of media attention and, in part, because of misplaced expectations of efficacy in some 
pathologies unsupported by scientific literature (Hill, 2015; Whiting et al., 2015).
Abbreviations: THCA, delta-9-tetrahydrocannabinolic acid; CBDA, cannabidiolic acid; THC, delta-9-tetrahydrocannabinol; 
CBD, cannabidiol; CBN, cannabinol; CE, collision energies
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To date, studies on the therapeutic efficacy of Cannabis 
in certain pathologies have yielded results that are, at best, 
contradictory and, generally, inconclusive given that the studies 
were carried out on inhomogeneous populations, used differing 
extraction processes, and administered differing dosages 
 (Bar-Lev et al., 2018). Moreover, the experiments were performed 
without proper control procedures and were administered 
by different routes. These uncertainties stem in part from 
legislative restrictions that, over time, have severely hindered the 
performance of rigorous clinical studies under controlled and 
comparable conditions. The legalization of Cannabis for medical 
use can pave the way for the gathering of reliable clinical and 
epidemiological data—fundamental for a clear definition of the 
clinical efficacy and the inherent risks, in a medical environment, 
of Cannabis.
In this context, Italian legislation has recently relaxed 
regulations on the administration of medical Cannabis for a 
number of medical conditions; it is now possible to use medical 
Cannabis in pain therapy, in the treatment of chemotherapy- 
and radiotherapy-induced nausea and vomiting, and to 
stimulate appetite in cases of cachexia, anorexia, cancer 
patients or AIDS patients suffering from loss of appetite. It 
is also being used for other conditions such as glaucoma and 
Tourette’s syndrome. Moreover, the cultivation of Cannabis for 
medical use was recently authorized, and, since 2016, a variety 
of Cannabis, known as FM2, has been available from the 
Pharmaceutical Chemical Military Facility in Florence, grown 
under authorization from the Ministry of Health. This material 
is available as ground, dried flowering tops containing delta-
9-tetrahydrocannabinol in concentrations ranging from 5% 
to 8% and cannabidiol from 7.5% to 12%. These percentages 
refer to the “total” content, that is, the sum of the components 
in acid form [delta-9-tetrahydrocannabinolic acid (THCA) 
and cannabidiolic acid (CBDA)] and decarboxylated form 
[delta-9-tetrahydrocannabinol (THC) and cannabidiol 
(CBD)] (President of the Italian Republic, 1990; Ministry of 
Health, 2015; Pharmaceutical Chemical Military Facility in 
Florence, 2019).
The phyto-complex of Cannabis plants is made up of more 
than 500 different constituents, of which a hundred or more 
belong to the cannabinoid class (Gould, 2015). Among the latter, 
even minor differences in structure can induce very different 
effects. The molecules of greatest interest from the point of view 
of their pharmacological activity are decarboxylated THC and 
decarboxylated CBD because they are more easily absorbed 
through the intestine (Grotenhermen, 2003). Therefore, the 
determination of the concentrations of these compounds in 
the preparations administered to patients is a fundamental 
prerequisite for therapeutic applications.
Current legislation in Italy allows Cannabis for medical 
purposes to be administered either orally or by inhaler. Regarding 
oral administration, according to the guidelines of the Ministry 
of Health, the first-choice pharmaceutical form is the decoction 
prepared in compliance with the official Ministry of Health 
procedure set out in the document “Recommendations for the 
prescribing doctor for the vegetable substance FM2 Cannabis 
flowering tops.” The inhaler route is only to be considered 
should the oral form not deliver the expected therapeutic 
effects or the patient’s doctor feels that it is more appropriate. 
Concerning oral administration, as well as the decoction, the 
current legislation allows for the administration of medical 
Cannabis as an oil extract (hereafter oil) provided that the oil 
content of active ingredients has been titrated by means of 
specific instrumentation (liquid or gas chromatography coupled 
with mass spectroscopy) (Ministry of Health, 2017; Ministry of 
Health, 2015).
The administration of titrated formulations, with a known 
quantity of active ingredient, obviously allows for a more uniform 
therapy and optimization of the risks/benefits. On this point, it 
is important to stress that although a number of preparation 
methods have been reported in scientific literature (Romano and 
Hazekamp, 2013; Citti et al., 2016; Società Italiana Farmacisti 
Preparatori, 2016), especially for oils, there is a lack of exhaustive 
comparative studies that examine from a technological aspect the 
Cannabis-based galenic formulation procedures currently in use 
for therapy.
In light of the above, the aim of this present work was to 
conduct specific formulation studies to design standard 
operating procedures for the preparation and optimization of 
Cannabis-based galenic formulations conforming with current 
health regulations. In particular, regarding the decoctions, the 
aims were to evaluate if concentrations were similar between 
preparations with a fixed ratio of Cannabis plant weight to 
solvent volume and, if it were possible, changing operating 
procedures to enrich the decoctions in terms of cannabinoid 
content. Concerning the oil, the principal aim was to evaluate 
how to set operating conditions to have the highest content of 
decarboxylated cannabinoids.
The application of a defined operating procedure, which 
produces reproducible results, is of particular relevance in 
obtaining standardized products. In particular, this is important 
in view of conducting further studies designed to optimize the 
administration of Cannabis for medical use based on patient 
characteristics. Furthermore, the application of standard 
procedures is important in view of performing clinical trials to 
evaluate the real correlation between cannabinoids and clinical 
outcomes in the real clinical practice.
MATERIALS AND METHODS
Materials for Galenic Preparations
All of the preparations described below were based on 
flowering tops from type FM2 Cannabis purchased from the 
Pharmaceutical Chemicals Military Facility in Florence. The 
titrated concentrations of active compounds in the unprocessed 
material (May 2017) were 0.40% ± 0.02% for THC, 5.74% ± 
0.18% for THCA, 0.29% ± 0.03% for CBD, and 8.70% ± 0.17% 
for CBDA. Consequently, the total THC content, calculated 
using the formula %THC tot = %THC + (0.877 × %THCA), was 
5.43% ± 0.15% and the total CBD content, calculated using the 
formula %CBD tot = %CBD + (0.877 × %CBDA), was 7.92% ± 
0.18%. The formulae adjusted for the differing molecular weights 
of the cannabinoid and carboxylic conjugative components of 
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each cannabinoid. Indeed, the decarboxylated form has a lower 
molecular weight than that of the carboxylated one because of 
the loss of a CO2 molecule. The ratio between the two molecular 
weights is 0.877 (Pacifici et al., 2017).
At the end of the experimentation period (June 2018), the 
titrated quantities of the active constituents in the plant material, 
calculated using the same equations, were reassessed and were 
2.54% ± 0.33% for THC, 2.97% ± 0.41% for THCA, 1.71% ± 
0.26% for CBD, and 6.29% ± 0.72% for CBDA. It follows that 
the total THC was equal to 5.14% ± 0.69% and total CBD was 
7.23% ± 0.95%. The other materials used for producing the 
preparations (olive oil and depured water) were purchased from 
a pharmaceutical supplies company (Farmalabor s.r.l., Canosa di 
Puglia, Bari, Italy) and complied with the relevant monograph of 
the European Pharmacopoeia (Eur.Ph).
Before being used for the formulations described below, 
the Cannabis plant material was ground for 60 s to produce a 
uniform blend.
Reagents and Materials for Quantitative 
Analysis
Olive oil (pharmaceutical grade), CBD, cannabinol (CBN), 
CBDA, cannabidiol-d3 (CBD-d3), THC, (-)-delta-9-
tetrahydrocannabinol-d3 (THC-d3), and isopropanol LC-MS 
grade were purchased from Sigma-Aldrich (Milan, Italy). THCA 
was purchased from LGC (Milan, Italy). Acetonitrile LC-MS 
grade was purchased from VWR (Milan, Italy).
HPLC-grade water was produced with Elix-coupled with 
Synergy-UV water purification system (Merck Millipore, Milan, 
Italy).
Preparation of the Decoction
The official procedure issued by the Italian Ministry of Health 
specifies that a decoction of FM2 Cannabis must be based on 
a mixture of Cannabis FM2 plant material and cold water in a 
weight-to-volume ratio of 1:1 (mg/ml). It advises against using a 
quantity of water less than 100 ml. The Cannabis plant material 
is added to the cold water; the water is brought to boil and 
allowed to simmer on low heat for 15 min in a covered vessel. 
The recommended maximum decoction time is 30 min, and 
the mix should be stirred regularly. The decoction is allowed to 
cool for 15 min, then stirred and filtered. The residue trapped 
in  the filter must be pressed with a spoon to recover as much 
liquid as possible and strengthen the final solution (Ministry of 
Health, 2017).
In accordance with the ministerial procedure, batches of 
decoction were prepared with a weight-to-volume ratio between 
plant material and solvent of 1:1 (mg/ml) (Table 1, Type A 
Decoctions).
In addition, further batches were prepared in compliance 
with the ministerial procedure (decoction and filtration) but 
with a modified weight-to-volume ratio between Cannabis 
FM2 flowering tops and solvent, namely, batches of decoctions 
with weight-to-volume ratios ranging from 2:1 to 10:1 (mg/ml) 
(Table 1, Type B Decoctions).
Common Methods for Preparing 
Cannabis Oils
Regarding Cannabis oils, there are, at present, three common 
methods for the preparation of Cannabis-based galenic 
preparations. The first two methods, which we shall call “RH” 
(Romano and Hazekamp, 2013) and “CC” (Citti et al., 2016), 
respectively, instruct that the Cannabis is finely chopped 
beforehand and then mixed with olive oil. The mixture is then 
heated (2 h immersed in a boiling water bath according to 
method RH; 2 h at 110°C according to method CC). The solution 
is then filtered to obtain the oily extract.
The third method, hereafter “SF” (Società Italiana Farmacisti 
Preparatori, 2016), instructs that the Cannabis is chopped finely 
and preheated at 115°C for 40 min. Thereafter, the Cannabis is 
added to the olive oil and further ground with a turbo emulsifier 
for 3 min. The mixture of olive oil and Cannabis is heated 
in a water bath of boiling water for 40 min and then filtered. 
Butyloxytoluene (BHT) is added to 0.02%.
All of the above methods are designed for a Cannabis plant 
weight–to–solvent volume ratio (mg/ml) of 100:1.
In the analysis of the experimental quantities of active ingredients 
that it is possible to recover from Type FM2 Cannabis plant using 
the three experimental methods above, the results were as follows:
• RH: 0.17% ± 0.09% THC, 0.05% ± 0.03% CBD, 0.18% ± 0.06% 
THCA, 0.47% ± 0.10% CBDA
• CC: 0.24% ± 0.08% THC, 0.23% ± 0.11% CBD, 0.24% ± 0.14% 
THCA, 0.67% ± 0.25% CBDA
• SF: 0.37% ± 0.08% THC, 0.70% ± 0.19% CBD, 0.07% ± 0.07% 
THCA, 0.15% ± 0.09% CBDA (Roda et al., 2018)
The most efficient method according to the results appears 
to be the SF procedure, which has a maximum titrated content 
of THC of 0.37% ± 0.08% (3.38 mg/ml) and a titrated CBD 
concentration of 0.70% ± 0.19% (6.40 mg/ml).
The commonly used extraction procedures to recover THC 
and CBD in oil form are not exhaustive. Therefore, the amount of 
THC and CBD present in the final preparations is lower than the 
declared one in the flowering tops.
Preparation of Oils for the Study
To prepare the Cannabis oil batches for this study, a defined 
weight of type FM2 Cannabis was added to a determined 
TABLE 1 | Types of decoction prepared.
Type of 
decoction
Ratio of Cannabis 
(mg)/solvent (ml)
Quantity of Cannabis 
(mg)
Volume of 
water (ml)
A-1 1:1 100 100
A-2 1:1 200 200
A-3 1:1 300 300
B-1 2:1 200 100
B-2 3:1 300 100
B-3 4:1 400 100
B-4 5:1 500 100
B-5 10:1 1,000 100
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volume of olive oil (mg/ml) in a ratio of 100:1 or 200:1. Batches 
of these oils were then heated in a water bath at 100°C with a 
magnetic stirrer for 30, 60, and 120 min, respectively. The oil was 
then filtered using a manual press through a filter of cotton or 
hydrophilic cotton gauze.
Before being added to the olive oil, some samples of the 
Cannabis material had been spread in a thin layer (maximum 
5 mm, preferably 1–2 mm) and placed in an oven at 140°C for 
30 min or at 115°C for 40 min. Other samples were added to the 
olive oil without preheating.
The temperatures applied were chosen for the following 
reasons: 115°C is near the decarboxylation reaction temperature 
for cannabinoids, which mainly takes place around 110°C, 
whereas 140°C was chosen as it is near the evaporation point of 
THC (145°C) (Wang et al., 2016).
The volumes of the prepared batches were between 5 and 
100 ml.
Table 2 lists the operating conditions applied during the 
preparation of the oils.
Analytical Methods
Chromatographic analysis (Carcieri et al., 2018) was performed 
by Acquity® UPLC system coupled with a TQD mass spectrometer 
(Waters, Milan, Italy). The chromatographic separation was 
carried out using an Acquity UPLC HSS T3 column (2.1 × 
30  mm, 1.8 µm) (Waters, Milan, Italy) at a constant 30°C. 
The chromatographic separation was obtained by a gradient 
of mobile phases A (acetonitrile and water in a ratio of 70:30 
+ 0.05% formic acid) and B (isopropanol and acetonitrile in a 
ratio of 80:30 + 0.05% formic acid) at a flow rate of 0.4 ml/min. 
The initial condition of the gradient was 100% solution A; after 
3.5 min, the mobile phase was brought to 100% solution B and 
kept there for 1.5 min; then the column was reequilibrated to the 
initial condition for 1 min (total time, 6 min). The autosampler 
was kept at 10°C, and the injection volume was 10 µl. Data 
acquisition, data processing, and system control were managed by 
MassLynx software (Waters, Milan, Italy). The mass spectrometer 
coupled to the UPLC system was set in positive ionization mode 
(ESI+) with a capillary voltage of 3.5 kV, a source temperature of 
150°C, and a desolvation temperature of 400°C. The flow rate of 
the nitrogen was 800 L/h for the desolvation, and the cone flow 
rate was 60 L/h.
Ion monitoring was performed in multiple reaction modes, 
with the mass transitions and collision energies (CEs) as reported 
here: CBD 315.14 → 193.04, CE 25; CBD-d3 318.10 → 196.14, CE 
25; THC 315.11 → 193.05, CE 25; THC-d3 318.19 → 196.12, CE 25; 
CBDA 359.15 → 219.07, CE 30; THCA 359.13 → 219.11, CEC 30; 
CBN 311.15 → 223.10, CE 20.
All the standard cannabinoid solutions necessary to create the 
calibration curve were diluted to concentrations between 1,250 
ng/ml and 5 ng/ml. CBD-d3 and THC-d3 were used as internal 
standards.
All of the samples to be analyzed were diluted with isopropanol 
to obtain a final concentration suitable for the range of the 
calibration curve.
Statistical Methods
The following values for each constituent of interest were 
calculated for the samples prepared according to the methods 
described in Tables 1 and 2 (Average concentration, the relative 
standard deviation, and the maximum and minimum quantities 
found in a specific quantity of finished product).
The data distribution was evaluated by the Shapiro–Wilk test. 
For the data with a normal distribution, comparisons between 
proportions and mean values were performed using t-test or 
ANOVA test; for the data with a non-normal distribution, the 
Wilcoxon rank-sum test or Kruskal–Wallis test was used instead.
To evaluate the variation of the final concentration of THC 
in the decoctions, linear regression was used. The dependent 
variable was THC concentration, and the independent variable 
was the initial amount of Cannabis used. The same analysis was 
performed to evaluate the variation of the final concentration of 
CBD in the decoctions.
The level of significance was fixed at 0.05; CI at 95%. 
Statistical analysis was performed with Stata®14 (StataCorp. 
2015. Stata Statistical Software: Release 14. College Station, TX: 
StataCorp LP).
RESULTS
Decoctions
Table 3 lists the quantities of THC, THCA, CBD, CBDA, and 
CBN found in the decoctions prepared using the procedures in 
Table 1. An analysis was performed on 146 samples of decoctions 
subdivided by the different preparation methods as reported in 
Table 1. Regarding decoctions prepared with methods A (A-1, 
A-2, A-3), the method with which was prepared the greatest 
number of samples was the method A-1. This corresponds 
to the one that provides the minimum dose of decoction for 
therapeutic purposes following the procedure approved by the 
Italian Ministry of Health. A-2 and A-3 methods were performed 
to confirm data when solvent volumes and Cannabis amounts, 
respectively, increase.
Based on the results obtained, it is possible to affirm that the 
methods A-1 to A-3, where the ratio of Cannabis plant weight to 
TABLE 2 | Type of oil prepared.
Method Ratio of 
Cannabis 
(mg)/solvent 
(ml)
Time in 
boiling 
water bath
Preheating 
temperature of 
the flowering 
tops
Time of 
preheating 
(min)
α-1 100:1 120 No preheating /
α-2 100:1 120 115°C 40
α-3 100:1 30 140°C 30
α-4 100:1 60 140°C 30
α-5 100:1 120 140°C 30
β-1 200:1 120 No preheating /
β-2 200:1 120 115°C 40
β-3 200:1 30 140°C 30
β-4 200:1 60 140°C 30
β-5 200:1 120 140°C 30
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solvent volume was maintained constantly (1:1) and for identical 
volumes of final product, there is no significant difference in 
the quantity of active molecules extracted (p > 0.05). However, 
regarding the methods B-1 to B-5, a significant difference in 
the quantity of active molecule extracted was found. For these 
methods, it was possible to observe that, given an identical 
volume of solvent used, the increase in raw material added leads 
to an increase in the quantities of both THC and CBD extracted. 
The linear regression analysis highlighted an average increase in 
THC of 0.016 mg/100 ml (p < 0.001) and an average rise in CBD 
levels of 0.017 mg/100 ml (p < 0.0001) for each 1 mg increase in 
Cannabis plant material added.
For all the decoctions prepared according to the methods 
A-1 to B-2, regardless of the ratio of Cannabis plant material 
weight to solvent volume used, the acidic cannabinoids were 
present in greater concentrations than the decarboxylated forms. 
For  the  decoctions prepared with methods B-3 to B-5, with 
respect to THC and THCA, the ratio changed: the decarboxylated 
forms were more present than the acidic ones. Considering the 
average content of active constituents in the decoctions prepared 
following methods A-1 to A-3, the average proportion of acidic 
forms to carboxylated forms is similar for all samples and, on 
average, equal to 2.30 ± 0.218 for THC and 4.85 ± 0.315 for CBD. 
Regarding the decoctions prepared with methods B-1 to B-5 
and considering the average content of active constituents, the 
proportions between the acidic forms and the decarboxylated 
forms diminish with the increase in the quantity of the plant 
form of the drug used: from a maximum of 2.19 for THC and 
6.75 for CBD for method B-1 to a minimum of 0.37 for THC and 
1.48 for CBD for method B-5.
CBN, a degradation product of THC, is present in minimal 
quantities in the samples of decoctions. The greatest quantities 
TABLE 3 | Quantity of active constituent in the decoctions.
Method Active molecule Number of samples 
analyzed
Average 
concentration of 
active molecule 
(mg/100 ml)
Standard deviation Concentration of 
active molecule: 
minimum value 
(mg/100 ml)
Concentration of 
active molecule: 
maximum value 
(mg/100 ml)
A-1 THC 39 0.87 0.41 0.26 2.47
CBD 1.07 0.43 0.27 2.42
THCA 1.81 0.55 0.88 3.09
CBDA 4.83 1.07 2.59 7.71
CBN 0.02 0.03 0.00 0.15
A-2 THC 6 0.72 0.15 0.53 0.88
CBD 1.01 0.14 0.86 1.24
THCA 1.81 0.89 0.58 2.52
CBDA 5.18 0.91 3.87 6.38 
CBN N.D.  N.D.  N.D. N.D. 
A-3 THC 6 0.83 0.26 0.59 1.31
CBD 1.09 0.26 0.90 1.62
THCA 1.91 0.78 0.92 2.60
CBDA 5.36 0.63 4.29 6.12
CBN N.D. N.D. N.D. N.D.
B-1 THC 4 1.33 0.24 1.08 1.54
CBD 1.42 0.31 1.01 1.65
THCA 2.92 0.44 2.45 3.44
CBDA 9.58 0.84 8.88 10.61
CBN N.D. N.D. N.D. N.D.
B-2 THC 4 2.44 0.43 1.81 2.80
CBD 2.04 0.46 1.36 2.39
THCA 2.95 0.58 2.13 3.37
CBDA 11.12 2.72 7.13 13.03
CBN N.D. N.D. N.D. N.D.
B-3 THC 4 3.86 0.35 3.61 4.36
CBD 3.12 0.22 2.79 3.27
THCA 3.52 0.03 3.49 3.57
CBDA 13.82 0.23 13.66 14.16
CBN N.D. N.D. N.D. N.D.
B-4 THC 38 6.24 1.32 3.10 8.55
CBD 6.01 1.65 2.42 8.65
THCA 4.04 1.14 1.79 7.15
CBDA 14.44 3.08 7.64 22.62
CBN 0.22 0.05 0.08 0.30
B-5 THC 45 13.81 3.89 6.68 20.30
CBD 14.44 4.51 5.02 20.68
THCA 5.14 1.43 1.75 8.24
CBDA 21.37 4.09 11.66 30.22
CBN 0.50 0.18 0.14 0.81
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are present in decoctions prepared with methods B-4 and B-5, in 
which the highest amount of Cannabis flowering tops was used.
Oils
Table 4 and Figure 1 report the quantities of THC, THCA, 
CBD, CBDA, and CBN detected in 93 samples of oils prepared 
using the different procedures listed in Table 2. Based on the 
results of the analyses, it can be affirmed that, considering the 
average content of active constituents, the proportion of acidic 
forms to decarboxylated forms is greater than 1 only for those 
methods that do not include a preheating phase for the raw 
Cannabis plant material (α-1 and β-1). As far as the methods 
that include a preheating phase are concerned, the quantity of 
TABLE 4 | Quantity of active constituent in oils.
Method Active constituent Number of samples 
analyzed
 Average 
concentration of 
active constituent 
(mg/ml)
Standard deviation Concentration of 
active constituent: 
minimum value 
(mg/ml)
Concentration of 
active constituent: 
maximum value 
(mg/ml)
α-1 THC 10 0.49 0.14 0.33 0.71
CBD 0.33 0.19 0.16 0.67
THCA 2.67 0.45 2.07 3.29
CBDA 4.40 0.84 3.12 5.45
CBN N.D. N.D. N.D. N.D.
α -2 THC 10 3.79 0.62 3.05 5.09
CBD 4.26 0.69 3.32 5.45
THCA 0.03 0.01 0.01 0.05
CBDA 1.17 0.22 0.82 1.43
CBN  N.D.  N.D.  N.D.  N.D. 
α-3 THC 6 3.35 0.22 3.07 3.65
CBD 5.22 0.40 4.87 5.75
THCA N.D. N.D. N.D. N.D.
CBDA 0.09 0.03 0.04 0.13
CBN 0.09 0.04 0.04 0.15
α-4 THC 6 3.92 0.14 3.67 4.09
CBD 5.44 0.34 4.92 5.94
THCA N.D. N.D. N.D. N.D.
CBDA 0.14 0.03 0.10 0.17
CBN 0.11 0.01 0.10 0.13
α-5 THC 12 3.22 0.47 2.44 3.88
CBD 4.98 0.67 4.07 6.58
THCA N.D. N.D. N.D. N.D.
CBDA 0.05 0.02 0.01 0.08
CBN 0.08 0.02 0.04 0.11
β-1 THC 4 1.94 0.11 1.82 2.09
CBD 1.40 0.16 1.18 1.55
THCA 6.76 0.51 6.15 7.40
CBDA 11.67 0.46 11.21 12.22
CBN N.D. N.D. N.D. N.D.
β-2 THC 6 7.52 0.83 6.47 8.68
CBD 9.33 1.05 8.25 11.12
THCA 0.11 0.04 0.07 0.17
CBDA 2.85 0.44 2.36 3.45
CBN N.D. N.D. N.D. N.D.
β-3 THC 6 7.59 0.52 6.93 8.30
CBD 11.96 0.84 10.79 12.89
THCA N.D. N.D. N.D. N.D.
CBDA 0.14 0.02 0.11 0.16
CBN 0.31 0.06 0.25 0.40
β-4 THC 27 8.04 1.83 5.20 12.19
CBD 13.05 1.78 9.85 15.58
THCA 0.03 0.02 0.01 0.07
CBDA 0.36 0.36 0.11 1.35
CBN 0.32 0.12 0.13 0.61
β-5 THC 6 7.76 0.66 6.86 8.45
CBD 13.15 0.94 12.04 14.64
THCA N.D. N.D. N.D. N.D.
CBDA 0.22 0.03 0.18 0.24
CBN 0.31 0.06 0.24 0.40
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active constituents in acid form is proportionally greater for 
those methods that apply a preheating temperature of 115°C 
for 40 min (α-2 and β-2) compared to that for methods that 
apply a preheating temperature of 140°C for 30 min (α-3, α-4, 
α-5, β-3, β-4, and β-5). Furthermore, the results demonstrate 
that the length of time in the water bath at 100°C appears to 
be uninfluential on the quantity of active molecule in the final 
product. In fact, there were no significant differences in the 
recovered quantities of THC and CBD in the oils prepared by the 
methods α-3, α-4, and α-5 with a ratio of Cannabis plant weight 
to solvent volume (mg/ml) of 100:1. The same is true for the oils 
prepared by the methods β-3, β-4, and β-5 with a ratio of plant 
weight to solvent volume of 200:1 (Figure 2).
In terms of active constituents in the oils produced, it is clear 
that, for preparations produced under identical conditions (time 
in boiling water bath, time and temperature of preheating), the 
proportion of the quantities of THC extracted with methods β 
compared to the quantities of THC extracted with methods α 
was, on average, 2.2. For CBD extraction, the same relationship 
is equal to an average value of 2.4.
CBN, a degradation product of THC, is present in minimal 
quantities in the samples of oils. CBN was not detected in those 
samples prepared with methods that do not include preheating 
of flowering tops (α-1 and β-1) or include preheating at lower 
temperatures (α-2 and β-2).
DISCUSSION
The analysis of the decoctions prepared using the different 
procedures demonstrated that, for a fixed ratio of Cannabis 
plant weight to solvent volume, the decoctions obtained have 
FIGURE 1 | Quantity of active constituents in oils.
FIGURE 2 | Comparison of the amount of active constituents in oils depending on the length of time in the boiling water bath if weight/volume ratio (mg/ml) between 
plant material and oil is 100:1 (α) and if it is 200:1 (β).
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the same characteristics in terms of concentration of active 
constituents of interest. Concerning the preparation methods 
in series B, the objective was to evaluate whether and if so, to 
what extent, it was possible to enrich the decoctions in terms of 
cannabinoid content in the decarboxylated form given that these 
molecules, even though they are easily absorbed in the intestine, 
not hydrophilic, and, therefore, present in low concentrations in 
the final decoction. As well as being foreseeable, this could lead 
to an ineffective therapy. In this context, the results obtained 
enabled us to observe that changing the ratio of Cannabis plant 
weight to solvent volume, as in methods B-1 to B-3 (ratios from 
2:1 to 4:1), did not lead to a significantly greater recovery rate 
of the active constituents compared to the decoctions prepared 
using the methods in series A. Regarding methods B-4 and B-5, 
with proportions of plant weight to solvent volume of 5:1 and 
10:1, respectively, the cannabinoid content was greater and, 
hence, for these decoctions, a greater number of tests were 
performed. Significantly, when the ratio of plant weight to 
solvent volume is greater or equal to 4:1, in this study, methods 
B-3 to B-5, the proportionality between THCA and THC turns 
out to be in favor of the decarboxylated form despite the use of 
an aqueous solvent.
Regardless of the fact that increasing the quantity of Cannabis 
plant material used means increasing the quantities of THC and 
CBD in the decarboxylated form in the final solution, the titrated 
quantity of the active components in the final decoction is greatly 
inferior compared to that in the oils. Thus, to ingest the same 
quantity of active molecule, the patient would have to ingest an 
extremely high volume of the decoction, with obvious drawbacks. 
By way of example, considering the most concentrated decoction, 
which is possible to obtain in terms of CBD (method B-5) and 
comparing it with the best of the oil preparations (method β-4), 
it is possible to calculate that the former is approximately 100 
times less concentrated compared to the latter; likewise, THC 
concentration is roughly 60 times less.
As for the oil preparations, based on the results obtained, 
it is possible to declare that the raw plant preheating phase is 
fundamental in obtaining oils with the decarboxylated forms 
of active constituents in proportionally higher concentrations. 
Therefore, these are more easily assimilated at the intestinal 
level. Turning to the variations applied to the preheating phase, 
the best results were observed by applying heat at a higher 
temperature and for a shorter duration (140°C for 30 min) rather 
than a lower temperature preheating with a longer duration 
(115°C for 40 min). With the aim of obtaining higher levels of 
decarboxylated forms of the active molecules contained in the 
raw plant, it is fundamental that, during the preheating, the 
layer of drug has a thickness no greater than 5 mm and ideally 
no greater than 1–2 mm so that the heat can spread uniformly 
throughout the layer of plant material.
With regards to the boiling water bath, the results demonstrate 
that the length of time tends to have no influence on the 
concentration of constituents in the final product. As a result, it 
appears clear that it is not necessary to overly extend (120 min) 
the water bath phase. As a precautionary measure, it is deemed 
that the recommended method for the preparation of Cannabis 
oils should have a water bath phase with a 60-min duration.
Considering the relationship between raw plant weight to 
solvent volume and the final concentration of active ingredients 
in the oils, it is possible to affirm that, by doubling the quantity of 
plant material used and under identical experimental conditions, 
the concentrations of THC and CBD in the oils increase by 
more than twofold. Indeed, the proportion of THC obtained 
using the methods β and the THC obtained using the methods 
α increase more than a factor of 2; similarly, for CBD. Therefore, 
the methods applied in series β led to a more efficient recovery 
of THC and CBD. Hence, considering this fact and the results 
regarding the water bath step, it has been established that the 
most efficient procedure for the preparation of Cannabis oils is 
β-4. An Italian patent application has been lodged with the Italian 
Office for Patents and Brands for the procedure for Cannabis oil 
production and is currently pending.
All of the preparations obtained in this project were produced 
by applying standard operating procedures specifically designed 
for this study. Despite this fact, the oils prepared using the 
recommended procedure β-4 are those with the highest 
standard deviation of all the preparations. The variability in 
the preparations may be linked, in general, to the fact that the 
vegetable matrix itself is not completely standardizable and, as is 
known, is affected by variations over time in the content of active 
ingredient.
The extractive capability of oil for cannabinoids was better than 
the water one. This was predictable because the cannabinoids have 
a lipophilic nature. The decoctions were prepared and analyzed 
because they are right now a frequent form of administration and 
recommended by the Italian Ministry of Health.
New formulations based on Cannabis oil are increasingly 
used. For instance, a study demonstrated that adding medical 
Cannabis oil to Alzheimer’s disease patients’ pharmacotherapy 
is safe and a promising treatment option in relieving behavioral 
and psychological symptoms of dementia (Shelef et al., 2016). 
Similarly, a prospective, open-label trial in children with Dravet 
syndrome demonstrated that a meaningful clinical reduction in 
seizures rates is achievable in pharmacoresistant participants by 
the addition of Cannabis oil to their concomitant antiepileptic 
regimens (McCoy et al., 2018). However the problem of oil 
standardization still needs to be addressed, as also recently 
documented by a study showing that adolescents and young 
adults with inflammatory bowel disease used Cannabis oil with 
a variety of delivery methods and concentrations and ratios of 
CBD to THC (Hoffenberg et al., 2019).
CONCLUSIONS
Based on the results obtained, it is possible to state that 
prescribing Cannabis-based decoctions, considering the low 
recovery rates of THC and CBD and, consequently, the high 
volume of preparation that the patient would have to ingest, 
should not be the first choice for Cannabis-based therapies, as is, 
unfortunately, currently recommended by the Italian Ministry of 
Health. Moreover, it is opportune to take into account the high 
raw material costs required to obtain the desired quantities of 
active molecules as previously discussed. In fact, to administer a 
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similar dose of THC and CBD, it would be necessary to utilize a 
considerably higher quantity of Cannabis to prepare a decoction 
compared to that required to prepare an oil-based preparation.
As for the oil preparations, procedure β-4 proved to be the 
most efficient method, with average recovery rates of 8.04 mg/ml 
of THC and 13.05 mg/ml of CBD, both in decarboxylated forms. 
These values are significantly higher compared to those with 
water-based extraction (decoctions) or other current oil-based 
extraction techniques.
Despite the excellent results achieved for the oils in terms of 
recovered active constituent concentrations, a consequence of the 
application of strict operating protocols, it is not possible to do away 
with the titration procedure for the oils, also taking into account 
that this is currently a requirement under Italian regulations.
At present, a study on the stability of the formulations, both 
in decoction and in oil forms, produced using the procedures 
developed as part of this research is being carried out.
Considering that the oils have a major drawback in that 
they have an unpleasant taste and smell, which may affect 
adherence to the therapy and hinder the use of a placebo arm 
in clinical research, the development of a pharmaceutical-grade 
formulation for oral administration is underway, exploiting the 
oil formulations to facilitate patients prescribed Cannabis-based 
medical therapies.
PATENT
An Italian patent application has been lodged with the Italian 
Office for Patents and Brands for the procedure for Cannabis oil 
production and is currently pending.
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